BioVeteria Life Sciences LLC, an Arizona-based bioscience company, has licensed an orally active cartilage and bone repair technology called ANABU from the Canadian Arthritis Network (CAN).
The technology showed the ability to stimulate cartilage cell proliferation, enhance bone repair and preserve cartilage and bone architecture in severe models of arthritis, according to its maker. Common disorders found in veterinary medicine such as osteochondrosis dessicans, fracture repair, bone cysts and navicular disease may be treated using this new technology.
“We are very excited to be working with CAN on this new technology,” said Craig Woods DVM, MS, MBA, general manager for BioVeteria. “The technology represents a significant advancement in veterinary orthopedics and proposes to improve our understanding on new techniques for cartilage and bone regeneration. In addition, our comparative work in dogs and horses will benefit our understanding for human medicine.”
The technology is an optimized glucosamine derivative and was developed by Tassos Anastassiades, MD, PhD, professor of medicine and biochemistry and head of the division of rheumatology at Queen's University in Kingston, Ontario. The lead compound was evaluated in vitro and in vivo.
“CAN is very pleased to be working with BioVeteria,” said Johnathan Riley, managing director of CAN. “Dr. Anastassiades has performed extensive research that has demonstrated striking benefits of ANABUTM in arthritis and osteoporosis animal models.”